Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show

Syros to Present on Core Drivers of Metastasis in Triple Negative Breast Cancer at San Antonio Breast Cancer Symposium

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that the company and its collaborators from the Whitehead Institute for Biomedical Research will present on the identification of core drivers of metastasis in triple-negative breast cancer (TNBC) in a poster presentation at the 2019 San Antonio Breast Cancer Symposium (SABCS), taking place December 10-14 in San Antonio, Texas.

The abstract for this presentation is now available online on the SABCS website at https://www.sabcs.org.

Details of the presentation are as follows:

Presentation Title: Epigenomic analysis of cancer stem cells (CSCs) from triple-negative breast cancer (TNBC) reveals p63 and p73 as core metastasis drivers
Session Date & Time: Friday, December 13, 7:00 a.m. ? 9:00 a.m. CT (8:00 a.m. ? 10:00 a.m. ET)
Session Title: Poster Session 4
Presenter: Matthew G. Guenther, Ph.D., Syros
Abstract Number: 2254
Program Number: P4-04-02
Location: Henry B. Gonzalez Convention Center, Hall 1

About Syros Pharmaceuticals:
Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust pipeline of development candidates, including SY-1425, a first-in-class oral selective RAR? agonist in a Phase 2 trial in a genomically defined subset of acute myeloid leukemia patients, and SY-5609, a highly selective and potent oral CDK7 inhibitor in investigational new drug application-enabling studies in cancer. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases, including sickle cell disease. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.

These press releases may also interest you

at 22:58
One-day mobile collections for COVID-19 testing specimens are continuing this weekend and into early next week, with the University of Mississippi Medical Center, Mississippi State Department of Health, Mississippi Emergency Management Agency and...

at 22:10
CureApp, Inc. (Head Office, Chuo-ku, Tokyo; President and CEO, Kohta Satake, M.D.), developer of software as a medical device "Digital Therapeutics" mobile applications, has launched a Phase 3 multicenter, randomized comparative study (clinical...

at 21:45
LiveShop Inc., an e-commerce platform to enable local shops to sell easily to their local buyers, has decided to offer their platform to all sellers in the U.S. and U.K. Company announcement: With social distancing and stay-at-home directives in...

at 20:05
Technavio has been monitoring the artificial intelligence (AI) in construction market and it is poised to grow by USD 1.13 billion during 2019-2023. The report offers an up-to-date analysis regarding the current market scenario, latest trends and...

at 19:30
The "Loudspeakers Global Market Report 2020" report has been added to ResearchAndMarkets.com's offering. This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares,...

at 19:30
Trepp, a leading provider of information, analytics, and solutions to the structured finance, commercial real estate (CRE), and banking markets has released its quarterly report of bank portfolio loan performance in commercial real estate,...

News published on 19 november 2019 at 07:05 and distributed by: